LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Altimmune, Inc. Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity at the American Diabetes Association?s 84th Scientific Sessions CI
Health Care Flat as Traders Wait More Obesity-Drug Updates - Health Care Roundup DJ
Transcript : Altimmune, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 09:20 AM
Altimmune, Inc. Presents Data at EASL International Liver Congress?? 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis CI
Transcript : Altimmune, Inc. Presents at UBS Obesity Therapeutics Day, May-23-2024 10:00 AM
Transcript : Altimmune, Inc., Q1 2024 Earnings Call, May 09, 2024
Earnings Flash (ALT) ALTIMMUNE Reports Q1 Revenue $5,000 MT
Altimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
North American Morning Briefing : More Earnings -2- DJ
Altimmune Shares Decline After Guggenheim Downgrade MT
Guggenheim Downgrades Altimmune to Neutral From Buy MT
Transcript : Altimmune, Inc. - Special Call
Altimmune Shares Slip Wednesday, After Reporting a Wider Q4 Net Loss and Dropping Prospective Treatment for Hepatitis B MT
Transcript : Altimmune, Inc., Q4 2023 Earnings Call, Mar 27, 2024
Altimmune, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Earnings Flash (ALT) ALTIMMUNE Reports Q4 Revenue $37,000 MT
Altimmune, Inc. Announces Impairment Loss for the Three Months Ended December 31, 2023 CI
North American Morning Briefing : Stocks Edge -2- DJ
North American Morning Briefing : Stock Futures -2- DJ
Altimmune, Inc.(NasdaqGM:ALT) added to S&P Biotechnology Select Industry Index CI
North American Morning Briefing : Inflation Data -2- DJ
Drugmakers deepen efforts to tap into booming market for obesity drugs RE
Zealand shares surge on liver drug data from Boehringer pact RE
Altimmune shares slide after Kerrisdale Capital takes short position RE
B. Riley Raises Altimmune's PT to $20 From $15 on Increased Obesity+NASH Therapeutics' Product Sales Projections; Keeps Buy Rating MT
Chart Altimmune, Inc.
More charts
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
7.14 USD
Average target price
20.57 USD
Spread / Average Target
+188.12%
Consensus
  1. Stock Market
  2. Equities
  3. ALT Stock
  4. News Altimmune, Inc.
  5. Earnings Flash (ALT) ALTIMMUNE Reports Q1 Revenue $5,000